<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03625505</url>
  </required_header>
  <id_info>
    <org_study_id>M16-802</org_study_id>
    <nct_id>NCT03625505</nct_id>
  </id_info>
  <brief_title>A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia</brief_title>
  <official_title>A Multicenter, Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Subjects With Relapsed/Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A dose-escalation study evaluating the safety, tolerability, pharmacokinetics (PK) and&#xD;
      efficacy of venetoclax, in combination with gilteritinib, in participants with relapsed or&#xD;
      refractory (R/R) acute myeloid leukemia (AML) who have failed to respond to, and/or have&#xD;
      relapsed or progressed after at least 1 prior therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 18, 2018</start_date>
  <completion_date type="Actual">August 31, 2021</completion_date>
  <primary_completion_date type="Actual">August 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RPTD) of Co-administered Study Drugs</measure>
    <time_frame>Up to approximately 6 months after the last participant is enrolled</time_frame>
    <description>The RPTD of co-administered venetoclax and gilteritinib will be determined during the dose escalation phase of the study. RPTD will be determined using available safety and pharmacokinetics data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified Composite Complete Remission (CRc)</measure>
    <time_frame>Up to approximately 6 months after the last participant is enrolled</time_frame>
    <description>Modified CRc rate is defined as the proportion of participants with documented complete response (CR) + CR with partial blood count recovery (CRp) + CR with incomplete blood count recovery (CRi) plus Morphologic Leukemia-Free State (MLFS) based on guidelines adapted from the International Working Group (IWG) for Acute Myeloid Leukemia (AML).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Cmax of Venetoclax</measure>
    <time_frame>Approximately 16 days after first dose of study drug</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Cmax of Gilteritinib</measure>
    <time_frame>Approximately 16 days after first dose of study drug</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Tmax of Venetoclax</measure>
    <time_frame>Approximately 16 days after first dose of study drug</time_frame>
    <description>Time to maximum plasma concentration (Tmax) of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Tmax of Gilteritinib</measure>
    <time_frame>Approximately 16 days after first dose of study drug</time_frame>
    <description>Time to maximum plasma concentration (Tmax) of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - AUCt of Venetoclax</measure>
    <time_frame>Approximately 16 days after first dose of study drug</time_frame>
    <description>Area Under the Plasma Concentration-time Curve (AUC) from Time 0 to Time of the Last Measurable Concentration (AUCt) of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - AUCt of Gilteritinib</measure>
    <time_frame>Approximately 16 days after first dose of study drug</time_frame>
    <description>Area Under the Plasma Concentration-time Curve (AUC) from Time 0 to Time of the Last Measurable Concentration (AUCt) of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - AUC0-24 Post-dose of Study Drug of Venetoclax</measure>
    <time_frame>Approximately 16 days after first dose of study drug</time_frame>
    <description>Area under the plasma concentration-time curve from 0 to 24 hours (AUC24) post-dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - AUC0-24 Post-dose of Study Drug of Gilteritinib</measure>
    <time_frame>Approximately 16 days after first dose of study drug</time_frame>
    <description>Area under the plasma concentration-time curve from 0 to 24 hours (AUC24) post-dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Complete Remission (CRc) Rate</measure>
    <time_frame>Up to approximately 6 months after the last participant is enrolled</time_frame>
    <description>CRc is defined as the proportion of participants with documented CR + CRp + CRi based on guidelines adapted from the International Working Group (IWG) for Acute Myeloid Leukemia (AML).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) of Modified Composite Complete Remission (CRc)</measure>
    <time_frame>Up to approximately 6 months after the last participant is enrolled</time_frame>
    <description>DOR of modified CRc will be defined as time from the first date achieving modified CRc to disease progression (including morphologic relapse) or death from any cause whichever is earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Remission (CR) + with Partial Hematologic Recovery (CRh)</measure>
    <time_frame>Up to approximately 6 months after the last participant is enrolled</time_frame>
    <description>It is defined as the proportion of participants achieving CR or CRh based on guidelines adapted from the International Working Group (IWG) for Acute Myeloid Leukemia (AML).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) of Complete Remission (CR) + Complete Remission with Partial Hematologic Recovery (CRh)</measure>
    <time_frame>Up to approximately 6 months after the last participant is enrolled</time_frame>
    <description>DOR of CR + CRh will be defined as time from the first date achieving CR and/or CRh to disease progression (including morphologic relapse) or death from any cause whichever is earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>From first dose of study drug until 30 days or 5 half-lives after discontinuation of study drug administration will be collected (up to approximately 4 years)</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Venetoclax + Gilteritinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Different combinations of dose levels for venetoclax in combination with gilteritinib will be administered to determine the recommended phase 2 dose (RPTD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Venetoclax + Gilteritinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive venetoclax in combination with gilteritinib at the dose determined in dose escalation portion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>tablet, oral</description>
    <arm_group_label>Dose Escalation Venetoclax + Gilteritinib</arm_group_label>
    <arm_group_label>Dose Expansion Venetoclax + Gilteritinib</arm_group_label>
    <other_name>ABT-199</other_name>
    <other_name>GDC-0199</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gilteritinib</intervention_name>
    <description>tablet, oral</description>
    <arm_group_label>Dose Escalation Venetoclax + Gilteritinib</arm_group_label>
    <arm_group_label>Dose Expansion Venetoclax + Gilteritinib</arm_group_label>
    <other_name>ASP-2215</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Should have an established, confirmed diagnosis of Acute Myeloid Leukemia (AML) by&#xD;
             World Health Organization (2016).&#xD;
&#xD;
          -  Should have failed at least 1 line of prior therapy (defined as failure to respond to&#xD;
             therapy, and/or progression during or after therapy).&#xD;
&#xD;
          -  Should have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1,&#xD;
             or 2.&#xD;
&#xD;
          -  Should have adequate hematologic, kidney and liver function as described in the&#xD;
             protocol.&#xD;
&#xD;
          -  For participants enrolling into the Expansion Cohort only: a documented FMS-like&#xD;
             Tyrosine Kinase (FLT3) mutation in bone marrow or peripheral blood, as described in&#xD;
             the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a diagnosis of acute promyelocytic leukemia (APL) or BCR-ABL-positive leukemia.&#xD;
&#xD;
          -  Has a history of other malignancies within 2 years prior to study entry, with&#xD;
             exceptions as described in the protocol.&#xD;
&#xD;
          -  Has active central nervous system leukemia.&#xD;
&#xD;
          -  Has a history of chronic New York Heart Association (NYHA) class IV heart failure.&#xD;
&#xD;
          -  Has a corrected QT interval of &gt; 450 ms.&#xD;
&#xD;
          -  Has a chronic respiratory disease that requires continuous oxygen use.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>David Geffen School of Medicin /ID# 200166</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Francisco Medical Center-Parnassus /ID# 200205</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-2202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer /ID# 200268</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136-1002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital /ID# 200230</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2927</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute /ID# 200623</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202-3700</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University /ID# 200349</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester /ID# 200346</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack Univ Med Ctr /ID# 200229</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College /ID# 200109</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp of the Univ of Penn /ID# 200348</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center at Texas Medical Center /ID# 206686</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com</url>
    <description>This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 8, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Acute Myeloid Leukemia (AML)</keyword>
  <keyword>Relapsed or Refractory AML</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>venetoclax</keyword>
  <keyword>gilteritinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

